Moenomycin is a natural product glycolipid that inhibits the growth of a broad spectrum of Gram-positive bacteria. In Escherichia coli, moenomycin inhibits peptidoglycan synthesis at the transglycosylation stage, causes accumulation of cell-wall intermediates, and leads to lysis and cell death. However, unlike Esc. coli, where 5-6 log units of killing are observed, 0-2 log units of killing occurred when Gram-positive bacteria were treated with similar multiples of the MIC. In addition, bulk peptidoglycan synthesis in intact Gram-positive cells was resistant to the effects of moenomycin. In contrast, synthetic disaccharides based on the moenomycin disaccharide core structure were identified that were bactericidal to Gram-positive bacteria, inhibited cell-wall synthesis in intact cells, and were active on both sensitive and vancomycinresistant enterococci. These disaccharide analogues do not inhibit the formation of N-acetylglucosamine-β-1,4-MurNAc-pentapeptide-pyrophosphorylundecaprenol (lipid II), but do inhibit the polymerization of lipid II into peptidoglycan in Esc. coli. In addition, cell growth was required for bactericidal activity. The data indicate that synthetic disaccharide analogues of moenomycin inhibit cell-wall synthesis at the transglycosylation stage, and that their activity on Gram-positive bacteria differs from moenomycin due to differential targeting of the transglycosylation process. Inhibition of the transglycosylation process represents a promising approach to the design of new antibacterial agents active on drug-resistant bacteria.
INTRODUCTION
Bacterial peptidoglycan synthesis initiates in the cytoplasm with the synthesis of UDP-N-acetyl-muramyl-pentapeptide (UDP-MurNAc-pentapeptide). The MurNAc-pentapeptide is transferred via the mraY gene product to a C55 undecaprenol phosphate carrier lipid monofunctional glycosyltransferase as mtgA. This pathway in Escherichia coli was recently reviewed (Holtje, 1998) . Moenomycin is a natural product inhibitor of bacterial peptidoglycan synthesis, acting at the stage of transglycosylation. Structurally it consists of a pentasaccharide chain linked to a C #& hydrophobic tail, moenocinol, via a phosphoric acid diester and a glycerol acid unit (Fig. 1) . Degradation studies reveal that some of the structural elements present in the parent molecule can be removed with retention of varying degrees of biological activity (for review see El-Abadla et al., 1999) . Although trisaccharide analogues of moenomycin are potent inhibitors of the in vitro transglycosylation reaction in Escherichia coli, they are 50-fold less active as antibacterial agents against Staphylococcus aureus (El-Abadla et al., 1999) . In contrast, specific disaccharide analogues maintain the ability to inhibit Esc. coli transglycosylase activity in vitro, while losing almost all ( 500-fold against Sta. aureus, and at least 700-fold against Streptococcus pyogenes) antibacterial activity (El-Abadla et al., 1999) . Esc. coli is the only organism used thus far in the study of the precise mechanism of antibacterial activity of moenomycin and its analogues. Moenomycin inhibits the in vitro transglycosylation reaction in Esc. coli (van Heijenoort et al., 1978 ; van Heijenoort & van Heijenoort, 1980) where the main cell-wall polymerization and cross-linking activity is due to penicillinbinding protein (PBP) 1B. The activity of PBP1A (and arguably PBP3 ; Goffin & Ghuysen, 1998 ; Adam et al., 1997) may also be sensitive to moenomycin-like inhibitors Matsuhashi et al., 1981) , as may PBP1C (Schiffer & Holtje, 1999) , but these data are not as definitive as the data for inhibition of PBP1B. In any event, moenomycin does not appear to inhibit the monofunctional transglycosylase from Esc. coli (Di Berardino et al., 1996) . Although moenomycin is not as potent against Esc. coli compared to Grampositive organisms (due to the outer-membrane barrier), its mode of action on whole cells is consistent with inhibition of cell-wall synthesis. Moenomycin causes rapid lysis of growing Esc. coli cells (van Heijenoort et al., 1987) , but not stationary-phase cells. Lysis, but not killing, was inhibited by the addition of Mg# + , consistent with the functioning of the autolytic system in Esc. coli. UDP-MurNAc-pentapeptide and the lipid-linked precursors lipid I and II accumulated when Esc. coli was treated with moenomycin (Kohlrausch & Holtje, 1991a) . All of these data with Esc. coli are consistent with the hypothesis that inhibition of transglycosylation leads to growth inhibition and killing even in the absence of lysis.
Much less is known about the effects of moenomycin on Gram-positive organisms. Given the poor activity of moenomycin on Esc. coli compared to Gram-positive bacteria, it seems likely that moenomycin evolved as an inhibitor of the much more sensitive Gram-positive organisms. Moenomycin does induce the vancomycinresistance pathway in Enterococcus faecalis (Mani et al., 1998) and Enterococcus faecium (Lai & Kirsch, 1996) , consistent with inhibition of cell-wall synthesis ; however, there are few additional data on the biochemical and physiological consequence of exposure of Grampositive organisms to moenomycin.
There is a growing need for new antibacterial agents that are active on drug-resistant Gram-positive pathogens. Our effort to discover novel analogues of moenomycin prepared by combinatorial synthesis (Kakarla et al., 1999 ; Sofia et al., 1999) led to identification of several related disaccharide analogues with unique antibacterial properties. Synthetic disaccharide analogues were identified that : (1) were bactericidal for Gram-positive organisms ; (2) were active against antibiotic-resistant bacteria (including vancomycinresistant enterococci) ; (3) killed growing, but not stationary-phase cells ; and (4) inhibited peptidoglycan synthesis in intact Ent. faecalis cells.
METHODS
Strains and growth conditions. Esc. coli ATCC 23226 was grown aerobically at 37 mC in a 10 l fermenter in Brain Heart Infusion medium (BHI) supplemented with 0n1% (w\v) Casamino acids (BHI\CAA) plus 1 % (w\v) glucose. The culture was grown exponentially to an OD '!! value of 6 (1 cm cell, Perkin Elmer Lambda 2S spectrophotometer) using aeration (1 l min − ") with air\oxygen to maintain a dissolved O # concentration of 5 %. The pH was maintained at 6n5. The culture was then cooled on ice, harvested by centrifugation at 6000 g for 20 min, and the cell pellet was stored at k80 mC. Cells were used for synthesis of peptidoglycan following permeabilization with ether as described below.
Esc. coli OV58 (pTA9) overexpressing MurG (Ikeda et al., 1992) was grown to an OD '!! 1n0 at 37 mC in a 10 l batch fermenter in BHI\CAA using 1 l min − " aeration with air and 150 r.p.m. agitation. The pH was not controlled. The cells were chilled on ice and harvested by centrifugation at 6000 g for 20 min. Cells were washed once with 5 mM Tris\HCl, pH 8n0 [50 ml (g wet pellet wt) − "], then resuspended in the same buffer to a concentration of 0n06 g wet wt ml − ". Membranes were prepared following lysis of cells at 20 000 p.s.i. (138 MPa) with a French press. The lysate was centrifuged at 6000 g for 10 min, and the resulting supernatant was ultracentrifuged at 200 000 g for 1 h. The pellet was resuspended in assay buffer and used as a source of enzymes for evaluation of lipid II formation (see below).
Determination of MIC values. The MIC of test compounds was determined in 96-well microtitre plates using twofold dilutions in BHI\CAA medium. Exponentially growing cells were diluted to approximately 5i10& c.f.u. ml − " and subjected to test compounds solubilized and serially diluted in DMSO. At a final concentration of 5 % (v\v), DMSO had no effect on cell growth or viability. Following an 18 h incubation at 37 mC, the OD '!! values were read on a microplate reader (Dynatec, model MR5000) immediately after plate mixing. The MIC was determined using the following criteria :
Determination of bactericidal activity. Cells were grown in BHI\CAA at 37 mC and test compounds were added to exponentially growing cells (OD '!! 0n08-0n1). Samples were incubated with shaking at 37 mC for 4 h, and viable cells determined over time by plating a dilution series in triplicate onto BHI\CAA agar plates that were incubated at 37 mC for 18-36 h prior to counting. Bactericidal activity was also determined using stationary cells prepared by overnight growth in BHI\CAA. Cell growth was shut off with either chloramphenicol (50 µg ml − "), tetracycline (20 µg ml − ") or moenomycin (10 µg ml − ") added to the culture. Viable counts were determined at the time of growth shut-off, then challenge compounds were added. Viable bacteria remaining after a 4 h incubation at 37 mC with shaking were determined by plating for c.f.u.
Preparation of ether permeabilized Esc. coli cells. Esc. coli ATCC 23226 cells were exposed to diethyl ether as described (Mirelman et al., 1976 ; Vosberg & Hoffmann-Berling, 1971 ) with minor modifications. Frozen bacterial cell pellets (grown and harvested as described above) were thawed on ice, washed twice by centrifugation (8000 g for 10 min) in Basic Medium (Vosberg & Hoffmann-Berling, 1971) , then permeabilized by a 1 min ether treatment. Cell suspensions were stored at k80 mC in the presence of DMSO (1 %, v\v) in 1 ml aliquots of 5-10 mg protein ml − ". A new aliquot was thawed immediately prior to use for each assay, washed with and resuspended in peptidoglycan polymerization assay buffer (see below).
Purification of UDP-MurNAc-pentapeptide from bacteria.
Ent. faecium strain MT10 Rev (Billot-Klein et al., 1997) , or Bacillus cereus ATCC 11778 was grown aerobically in a 10 l fermenter in BHI\CAA medium. The substrate UDPMurNAc-pentapeptide, containing either -lysine or mesodiaminopimelic acid, was isolated from these cells as described (Kohlrausch & Holtje, 1991b) , with minor modifications. The concentration of purified nucleotide sugars was determined using the molar extinction coefficient of uridine, ε M, #'# l 1i10%. The UDP-MurNAc-pentapeptides were authenticated by mass spectrometry, and lyophilized for storage at k80 mC.
Biotin labelling of UDP-MurNAc-pentapeptide. UDPMurNAc-pentapeptide (containing -lysine) was labelled (Men et al., 1998) using solid sulfo-NHS-LC Biotin (Pierce). The UDP-MurNAc-pentapeptide-biotin conjugate was purified by HPLC using a Supelcosil C-18 (4n6 mmi25 cm) column eluted at 1n0 ml min − " with an elution profile of potassium phosphate (10 min), water (5 min), followed by a 30 min linear gradient to 50 % methanol\water (v\v) (Branstrom et al., 2000b) . Peptidoglycan polymerization assay. Peptidoglycan synthesis was determined in ether-treated bacteria (ETB) as described (Allen et al., 1992 (Allen et al., , 1996 , with modifications for adaptation to automated liquid handing equipment. GFC filter-bottom 96-well microplates (Millipore) were used throughout. Assay buffer was prepared fresh daily from 10i stock solutions, and contained : 50 mM Tris\HCl (pH 8n3) ; 50 mM NH % Cl ; 20 mM MgSO % ; 0n15 mM -aspartic acid, 100 µg tetracycline ml − " and 0n5 mM β-mercaptoethanol (reagents from Sigma Chemical). Reaction mixtures (100 µl) also contained : (model 1450 ; EG & G Wallac) . Reaction blanks were defined as corrected c.p.m. retained on the filter either in the absence of UDP-MurNAc-pentapeptide or in the presence of a concentration of reference compound (moenomycin) completely suppressing incorporation of radiolabel. Concentration-response curves were analysed by non-linear regression using a four-parameter logistic model fitted and plotted with GraphPad Prism (v. 2.01, GraphPad Software). IC &! values given in the text represent means from 2-10 separate experiments, each curve using at least 5-7 concentrations of test compound in duplicate wells. Effect of drugs on peptidoglycan degradation. The stability of peptidoglycan made during various time periods of the reaction using ether permeabilized Esc. coli cells was examined in the presence of the disaccharide analogues. Reactions were set as given above, and initiated by addition of warmed ether permeabilized cells (20 µl, 30 µg protein per well) to all reaction wells. Vehicle or test compound (20 µl) was then added sequentially to appropriate wells at t ! (120 min incubation with drug), t $! min (90 min incubation with drug), t '! min (60 min incubation with drug), t *! min (30 min incubation with drug) and t "#! min (0 min incubation with drug). At t "#! min, reactions were terminated by addition of 100 µl 20% (w\v) TCA to all wells, followed by shaking for 30 s on an orbital plate shaker. Samples were then processed (see above) and radioactivity incorporated into peptidoglycan determined as described above. Peptidoglycan synthesis in intact cells. Ent. faecalis ATCC 29212 was grown in BHI\CAA medium at 37 mC and used to measure incorporation of radiolabelled lysine into peptidoglycan as described by Allen et al. (1996) with minor modifications for adaptation to microtitre filtration. Briefly, this involved treatment of cells with 50 µg tetracycline ml − " plus 100 µg chloramphenicol ml − " for 30 min to inhibit protein synthesis. Varying concentrations of drugs were added to cells, and reactions were initiated by addition of ["%C]-lysine [0n25 µCi (9n25 kBq) per reaction, 329 mCi (12n2 GBq) mmol − " ; Amersham]. Reactions were stopped, samples processed and data analysed as described above for the peptidoglycan polymerization assay. Incorporation was linear for 60 min, and 15 000-20 000 d.p.m. were incorporated into control samples.
Inhibition of transglycosylation and accumulation of lipid
intermediates. Inhibition of mature (cross-linked) and immature (nascent) peptidoglycan, and accumulation of lipid intermediates was determined as described (Ge et al., 1999) . Briefly, this method uses 1n0 mg penicillin G ml − " to inhibit cross-linking of peptidoglycan into mature strands, and follows accumulation of lipid intermediates by extraction into butanol-pyridinium acetate.
Lipid II formation assay. The assay was performed as described by Branstrom et al. (2000b) . Reaction components consisted of bacterial membranes (25 µg protein), 0n5 µM UDP-["%C]GlcNAc [$ 20 000 d.p.m. (333 Bq)], 10 µM biotinylated UDP-MurNAc-pentapeptide and 0n1% (v\v) Triton X-100, all in 50 µl assay buffer (50 mM Tris\HCl, pH 8n0, 42 mM Mg(Ac) # and 208 mM KCl). Reactions were preincubated without radiolabelled UDP-GlcNAc for 10 min at room temperature to allow formation of lipid I and then lipid II formation was initiated by addition of UDP-GlcNAc. Lipid II synthesis was allowed to proceed for 15 min at room temperature before being terminated with 25 µl 1% (w\v) SDS. Incorporation of labelled GlcNAc continued for 40-50 min in control reactions. Lipid II was identified by mobility using paper chromatography (van Heijenoort et al., 1992) and specific capture with Softlink avidin resin (Promega) (see below).
Streptavidin-bead capture. Capture of biotinylated lipid II was as previously described by Branstrom et al. (2000b) . Binding buffer (10 mM Tris\HCl, pH 8n0, 150 mM NaCl, 0n2% v\v Triton X-100) either 500 µl or 100 µl, was added to Eppendorf tubes or 96-well filter plates, respectively, containing lipid II reaction mixtures. Tetralink (Promega) tetrameric avidin resin (35 µl as supplied) was added to each reaction to allow for capture of product. For the tube assay, samples were gently mixed for 1 h at room temperature, centrifuged for 3 min at 1500 g, and then washed four times with 500 µl binding buffer. Reactions run in filter plates were vacuum filtered and washed five times with 200 µl binding buffer. The washed beads from Eppendorf tubes were resuspended in buffer, mixed with scintillation cocktail, and counted in a scintillation counter to determine the amount of lipid II product made. Softlink monomeric avidin resin (Promega) was substituted for Tetralink resin when the captured product needed to be released for further analysis by paper chromatography (Anderson et al., 1966) .
Polymerization of lipid II into peptidoglycan. Polymerization of lipid II into peptidoglycan was monitored in situ (Branstrom et al., 2000a) . The first step of this assay allowed synthesis and accumulation of lipid II in a reaction mixture containing Esc. coli membranes (0n5 mg ml − "), UDP-MurNAc pentapeptide (20 µM) and radiolabelled UDP-GlcNAc (0n5 µM) in reaction buffer (50 mM Tris ; pH 8n0 ; 42 mM Mg(Ac) # ; 208 mM KCl ; 0n1% v\v Triton X-100 ; and 10 % v\v DMSO). Reactions were incubated for 2 h at room temperature to accumulate endogenous lipid II. Inhibitors were added prior to removal of Triton X-100 by the addition of Detergent-Out resin (GenoTechnology). Reactions proceeded for an additional 2 h at room temperature to allow conversion of lipid II into peptidoglycan, which was monitored by ascending paper chromatography (Anderson et al., 1966) .
Effect on Candida albicans growth and glucan synthesis.
Candida albicans strain CCH442 was grown in BHI\CAA to OD '!! 0n1, and drugs added. Growth and viable counts were monitored. Microsomes were prepared as previously described for assay of 1,3-β-glucan synthesis , monitoring incorporation of ["%C]glucose from UDPglucose into glucan.
In vitro cytotoxicity. LD
&! values for cytotoxicity of moenomycin and the synthetic disaccharide analogues were determined in three mammalian cell lines -NIH3T3, HL-60 and HBL-100. Test compounds diluted in OptiMEM (Gibco-BRL), or medium alone were incubated for 6 h at 37 mC. Medium was removed and cells were incubated with fresh medium for 18 h. A Cytolux (EG & G Wallac) luminescent assay kit and Wallac Trilux plate reader were used to screen for cell viability as described by the manufacturer. At least eight concentrations of test compound were used to determine the LD &! computed by a four-parameter logistic fit of percentage cell viability versus drug concentration.
Antibiotics. Moenomycin A was isolated and purified by standard preparative HPLC from commercial sources (Flavomycin ; Hoechst). Reference standard antibiotics were purchased from Sigma. All synthetic disaccharide analogues were prepared at Incara Research Laboratories as described by Sofia et al. (1999) .
RESULTS

Antibacterial activity of moenomycin analogues
Moenomycin possesses potent antibacterial activity against Gram-positive bacteria, but is much less active against Gram-negative bacteria (van Heijenoort et al., 1987) . However, moenomycin is quite active against Esc. coli BAS849, containing a defect in outer-membrane structure (Table 1 ). This strain of Esc. coli was isolated as a mutant hypersuseptible to antibiotics (Sampson et al., 1989) . The disaccharide product of moenomycin degradation, TS0514 (Fig. 1) , was devoid of antibacterial activity (MIC 100 µg ml −" ) as reported by El-Abadla et al. (1999 ; see p. 706 therein) in their later assays.
Starting with the basic lipid-linked disaccharide moenomycin core, we initiated a programme to produce synthetic disaccharide analogues that regained antibacterial activity. Analogues TS30153, TS30663 and TS30888 (Fig. 2) are related in structure to the moenomycin E-F disaccharide TS0514 (Fig. 1 ). All contain a lipid anchor (C "# lipid), and possess a β-linked disaccharide similar to the moenomycin E-F disaccharide. They differ from the moenomycin disaccharide by the substitution of a nitrogen functionality in place of the C-3 oxygen of moenomycin and the absence of the C-4 methyl group of the F-sugar. In addition, TS30153 replaces the moenomycin glucosamine E-unit with a galactosamine sugar. All contain aromatic moieties attached to the saccharide units (units E and F, see Figs 1 and 2). The disaccharide analogues were active on Gram-positive bacteria (Table 1 ) and two showed MICs were determined by microbroth dilution in BHI\CAA media on two or more occasions, and were identical or within twofold. Note : TS30153, TS30663 and TS30888 are given as compounds 23, 21 and 18, respectively, by Sofia et al. (1999) . MIC values for TS0514 (moenomycin disaccharide degradation product) on these strains was 100 µg ml −" (from El-Abadla et al., 1999 activity on the supersensitive Esc. coli strain. They were at least 10-20-fold more active than the moenomycin disaccharide degradation product (TS0514), although they were two orders of magnitude less potent than moenomycin itself. Analogues TS30153 and TS30663 are less potent (2-16-fold) than vancomycin on vancomycin-sensitive Gram-positive bacteria, but they maintain their efficacy and potency on vancomycinresistant bacteria (Table 1 ). The disaccharide analogues were also active on Ent. faecium ATCC 49624 (Table 1) , a naturally occurring isolate that is resistant to moenomycin. Thus, derivatization of the modified moenomycin disaccharide core and attachment of a less complex lipid chain led to molecules with a novel spectrum of antibacterial activity.
Bactericidal activity of moenomycin and disaccharide analogues
Our studies revealed that moenomycin had differential bactericidal activity on Gram-negative and Gram-positive bacteria. Moenomycin is bactericidal to Esc. coli and will cause rapid cell lysis (van Heijenoort et al., 1987) . Killing was also observed in the absence of lysis when Mg# + was added to cells to prevent autolysis. We obtained similar results with our hypersusceptible strain of Esc. coli (data not shown). The survival frequency was 3n3i10 −% and 2n1i10 −& in the presence and absence of Mg# + , respectively, 4 h after treatment with 0n25 µg moenomycin ml −" (10 times the MIC level of drug).
In contrast, moenomycin showed only slight bactericidal activity on Gram-positive bacteria. Moenomycin gradually inhibited growth of Ent. faecalis at concentrations ranging from 4 to 600 times MIC, and the optical density gradually increased threefold by 4 h after drug addition (data not shown). Sta. aureus and Sta. epidermidis showed slightly faster growth shut-off occurring 1 h after treatment with moenomycin at 10 or 100 times the MIC, and the optical density declined slightly between 1 and 4 h post-drug addition (Fig. 3) . The timing of growth shut-off was similar at 100 times MIC, but the decline in optical density was slightly faster (data not shown).
In addition to moenomycin being weakly bactericidal to Gram-positive bacteria, the degree of bactericidal activity was also dependent on the species tested. Less than 1 log unit of killing occurred after 4 h when Ent. faecium strain RLA1 (Fig. 4b) or Ent. faecalis (not shown) were treated with up to 500 times the MIC of moenomycin. Similar data were obtained with Sta. aureus when treated with 10-100 times MIC of moenomycin (Fig. 4a and data not shown). We tested high levels of moenomycin to validate that the low level of killing was inherent to moenomycin, and not just dependent on the amount used. Three log units of killing occurred when Sta. epidermidis was treated with 100 times the MIC of moenomycin (Fig. 4a) and this was reduced to 2 log units of killing at 10 times MIC (data not shown). In contrast, TS30663 (Fig. 4a ) killed 4-6 log units when Grampositive bacteria were treated with four to eight times were determined by plating serial dilutions at various times following drug addition. Sta. epidermidis ATCC 12228 : control ( ); 2n5 % DMSO (=) ; moenomycin (W) ; TS30663 (5). S. aureus ATCC 29213 : control (); 2n5 % DMSO (>) ; moenomycin (X) ; TS30663 (4). (b) Cells were grown in BHI/CAA and moenomycin added to 100 times MIC of strain RLA1, or disaccharide analogues added to eight times MIC. c.f.u. were determined by plating serial dilutions at various times following drug addition. Ent. faecium RLA1 : 2n5 % DMSO (); moenomycin (>) ; TS30663 (X); Ent. faecium strain ATCC 49624, which is naturally resistant to moenomycin : 2n5 % DMSO (4); TS30663 ($).
MIC for 4 h. Similar results were obtained with TS30153 and TS30888 (data not shown). The multi-drug-resistant Ent. faecium strain RLA1 (Fig. 4b) and the vancomycinresistant Ent. faecalis strain CL5244 (not shown) were also killed 3-5 log units when treated with four to eight times MIC of the disaccharide analogue TS30663. Ent. faecium strain ATCC 49624 was resistant to moenomycin (Table 1 ) and thus not killed by moenomycin, but was killed by TS30663 (Fig. 4b) . c.f.u. ml −" were determined at time 0 and the first drug was added (50 µg chloramphenicol ml −" , 20 µg tetracycline ml −" or 10 µg moenomycin ml −" ). After growth shut-off due to the first drug, cultures were diluted in medium (to OD '!! l 0n1) containing the same concentration of first drug and c.f.u. ml −" were determined in triplicate. Challenge drug was then added (TS30153, TS30663) at 4-8 times MIC. c.f.u. ml −" were determined again at 4 h after addition of challenge drug. Growing cells were also challenged with test drug (TS30153 and TS30663), 50 µg ml −" at OD '!! l 0n1 for 4 h, and survival frequency determined. Values in parentheses are from a repeat experiment.
Non-growing bacterial cells are characteristically re-
Drug treatment
Survival frequency* Survival non-growing/growing * The viable cell count after treatment with the first drug (growth shut-off) was normalized to 1n0 and survival frequency determined for treatment with the challenge drug. sistant to killing by cell-wall synthesis inhibitors. Accordingly, stationary-phase cells were resistant to killing by the disaccharide analogues, yielding survival frequencies of 0n18-0n41 that were 10$-10& greater than survival frequencies for growing cells (data not shown).
In addition, the bactericidal activity of disaccharide analogues was abolished when bacteria were pretreated with tetracycline, chloramphenicol or moenomycin (Table 2 ). Tetracycline and chloramphenicol inhibited growth, though both caused minimal killing by themselves ( 1 log unit). Bactericidal activity of the disaccharide analogues was abolished in chloramphenicoland moenomycin-pretreated cells, and nearly abolished in tetracycline-pretreated cells by factors of 10$-10& compared to growing cells.
Inhibition of peptidoglycan synthesis in permeabilized Esc. coli cells
The disaccharide analogues TS30663, TS30153 and TS30888 all inhibited peptidoglycan synthesis in etherpermeabilized Esc. coli cells (Table 3) 10n6, 15n2 and 6n9 µg ml −" , respectively. This assay is sensitive to a range of known inhibitors (including moenomycin and vancomycin) of peptidoglycan syn- thesis (Table 3) . Moenomycin is the most potent of these inhibitors on both a mass and molar basis with an IC &! of 0n025 µg ml −" (0n016 µM). The disaccharide analogues were 400-600-fold (based on mass and molarity, respectively) less potent compared to moenomycin in their ability to inhibit peptidoglycan synthesis in ether-treated Esc. coli. However, the disaccharide analogues were of the same relative potency as vancomycin in this in vitro system. In all cases, complete inhibition of peptidoglycan synthesis at high doses of drug was documented by spotting a sample of the reaction mix for paper chromatography (Anderson et al., 1966) and determining the amount of radioactivity in peptidoglycan present at the origin.
Inhibition of cell-wall synthesis in Ent. faecalis
The disaccharide analogues also inhibited cell-wall synthesis in intact Ent. faecalis cells (Table 3) of vancomycin on both a mass and molar basis in this assay (Table 3) . Surprisingly, moenomycin itself did not show inhibition even when tested at 200 µg ml −" .
Lipid II and peptidoglycan synthesis using Esc. coli membranes
Neither moenomycin, TS30153, TS30663, nor TS30888 inhibited formation of lipid II from UDP-MurNAcpentapeptide and UDP-GlcNAc in an assay designed to measure only lipid II synthesis (see Branstrom et al., 2000b ; data not shown). By contrast, in the same assay, tunicamycin (an inhibitor of MraY) inhibited lipid II formation by 50 % at 1 µg ml −" , as expected. We confirmed that peptidoglycan was in fact formed by Esc. coli membranes from biotinylated UDP-MurNAc-pentapeptide during a 2 h incubation (Fig. 5a ). As expected, moenomycin, at 400 times its IC &! , inhibited peptidoglycan formation and caused accumulation of lipid II (Fig. 5b) . TS30153 also inhibited peptidoglycan formation at six times its IC &! (highest concentration testable), but not formation of lipid II (Fig. 5c) , and no accumulation of lipid II relative to controls was observed. Similar results were obtained for TS30888 and TS30663 (data not shown). Lipid II was identified by mobility, incorporation of labelled GlcNAc and the presence of biotin (from UDP-MurNAc-pentapeptide) as assessed by capture with Softlink avidin resin (not shown).
Direct analysis of inhibition of lipid II polymerization into peptidoglycan
Inhibition of transglycosylation was monitored by following conversion of endogenous, radiolabelled lipid II into peptidoglycan. Moenomycin was a potent inhibitor with an IC &! of 9n6 ng ml −" (95 % confidence interval l 8n2-11n2 ng ml −" ). TS30663 also gave a typical sigmoidal concentration-response curve in the assay and an IC &! value of 27n8 µg ml −" (95 % confidence interval l 20n33-38n04 µg ml −" ). IC &! values for TS30153 and TS30888 were estimated at 40 and 15 µg ml −" , respectively, by single point analysis (data not shown).
Analysis of potential peptidoglycan degradation
The disaccharide analogues inhibited incorporation into peptidoglycan of radiolabelled ["%C]GlcNAc from UDPGlcNAc (Table 3 ). This could be due to either inhibition of peptidoglycan synthesis, or stimulation of peptidoglycan degradation. We thus examined the stability of newly synthesized peptidoglycan made during various time periods over the course of the 2 h incubation. Peptidoglycan synthesis was allowed to occur for various times, and then disaccharide inhibitors were added. Peptidoglycan made prior to disaccharide addition, even during the first 30 min, was stable during the remainder of the 2 h incubation (Fig. 6 ). These data show that the disaccharide analogues inhibit formation of peptidoglycan, but do not stimulate its degradation.
Inhibition of mature and immature peptidoglycan in
Esc. coli
Like moenomycin, TS30663 inhibited synthesis of both mature and immature peptidoglycan (Fig. 7) , consistent with inhibition at the transglycosylation stage. Whereas moenomycin caused a 50 % increase in butanolextractable lipid II, only slight accumulation of lipid intermediates occurred with TS30663 treatment when penicillin was included to inhibit cross-linking of peptidoglycan.
C. albicans growth and glucan synthesis
Growth of C. albicans strain CCH442 was not altered by 50 µg disaccharide analogues ml −" (data not shown). In addition, disaccharide analogues failed to inhibit 1,3-β-glucan synthesis by microsomes from the same strain, when tested at 50 µg ml −" . Thus, the antimicrobial effects of these novel disaccharide analogues appeared specific for bacterial cell-wall synthesis.
In vitro cell viability
The LD &! for cytotoxicity in three mammalian cell lines (NIH3T3, HL-60 and HBL-100) averaged 15 µg ml −" for TS30663 and 50 µg ml −" for both TS30888 and TS30153. A concentration of 100 µg moenomycin ml −" failed to exhibit significant effects on viability in any of these cell lines (data not shown). The differential antimicrobial effects that were observed at MIC levels for moenomycin versus novel disaccharide analogues reported in the present studies are, therefore, unlikely to be due to non-specific cytotoxicity.
DISCUSSION
Moenomycin is one of the few known inhibitors of the essential transglycosylation reaction catalysing polymerization of lipid II into bacterial peptidoglycan. Moenomycin has a broad spectrum of activity against Gram-positive bacteria, and is active in vivo in mouse models of bacterial infection (von Wasielewski et al., 1965) . However, moenomycin itself has no clinical utility because it is poorly absorbed. It shows low systemic toxicity in animals and is used as an animal feed ' growth promoter ' under the Hoechst trademark Flavomycin (Huber, 1979) . The minimal structural requirements for antibacterial activity consist of a trisaccharide linked to a C #& hydrophobic tail, moenocinol, via a phosphoric acid diester and a glycerol acid unit, with the disaccharide (Fig. 2) being nearly devoid of antibacterial activity (El-Abadla et al., 1999) . Essential components of the basic moenomycin structure likely interact with the donor or acceptor sites on the transglycosylase enzyme, thus inhibiting enzyme interaction with the normal lipid II substrate and\or nascent lipid-linked peptidoglycan. However, most of the studies investigating the mode of action of moenomycin on bacteria were conducted with the Gramnegative bacterium Esc. coli.
A programme was initiated based on synthesis of analogues of the moenomycin disaccharide structure (Kakarla et al., 1999 ; Sofia et al., 1999) . Our rationale was that creating new sites of interaction with amino acid residues adjacent to the active site on a target enzyme could enhance even the weak activity reported for disaccharide analogues related to the moenomycin core structure (El-Abadla et al., 1999) . Simplified lipids were also included in the synthetic scheme in place of the C #& moenocinol. Combinatorial chemistry, using synthetic strategies developed in our laboratory (Sofia et al., 1999 ; Kakarla et al., 1999) was used to explore chemical modification of the disaccharide core. Several active compounds were identified and three (TS30153, TS30663 and TS30888) were investigated in detail.
The three disaccharide analogues studied all possess antibacterial activity against Gram-positive bacteria, including strains resistant to vancomycin, with MIC values ranging from 3 to 12 µg ml −" . Since the moenomycin disaccharide degradation product (TS0514) is inactive as an antibacterial agent, our data demonstrate that appropriate derivatization of the E and F units can lead to antibacterial agents active on both sensitive and resistant bacteria. These disaccharide analogues are active on vancomycin-resistant strains and are nearly as potent as vancomycin on vancomycin-sensitive strains.
Almost all the data in the literature pertaining to inhibition of transglycosylase activity by moenomycin and its physiological consequences on bacteria, comes from the study of Esc. coli (Hara & Suzuki, 1984 ; Kohlrausch & Holtje, 1991a ; Tamura et al., 1980 ; van Heijenoort et al., 1978 van Heijenoort et al., , 1987 van Heijenoort & van Heijenoort, 1980) . Moenomycin is rapidly bactericidal to growing Esc. coli, resulting in bacterial lysis and cell death, although lysis is not required for loss of viability. In contrast, our data reveal that the bactericidal activity of moenomycin is limited for Gram-positive bacteria. Only 1-2 log units of killing occurred when Grampositive bacteria were treated with 5-10 times the MIC value of moenomycin. Killing was increased to 3 log units when the most sensitive species, Sta. epidermidis, was treated with 100 times the MIC of moenomycin. In contrast, the disaccharide analogues killed 3-6 log units when Gram-positive bacteria were treated with four to eight times the MIC. Thus, modifications to the disaccharide core resulted in the discovery of novel bactericidal analogues contrasting with the parent compound that had only bacteriostatic effects in Grampositive bacteria.
Our data revealed that disaccharide analogues blocked peptidoglycan synthesis in ether-permeabilized Esc. coli at some point between the synthesis of lipid II and its polymerization into peptidoglycan by transglycosylation. This in vitro system requires the concerted action of MraY, MurG, lipid II translocation and recycling, and polymerization of lipid II into peptidoglycan. Evidence supporting inhibition of the transglycosylation stage by the synthetic disaccharide analogues is as follows. Neither the disaccharide analogues nor moenomycin inhibited lipid II synthesis in a system that depended on the functioning of MraY and MurG. However, both moenomycin and the disaccharide analogues did inhibit conversion of lipid II into peptidoglycan. Disaccharide analogues and moenomycin in-hibited synthesis of both mature and immature peptidoglycan, data consistent with inhibition at the transglycosylase stage. However, the disaccharide analogues caused less accumulation of lipid II than moenomycin. In addition, stimulation of peptidoglycan degradation was ruled out, since peptidoglycan made during various time periods in ether permeabilized Esc. coli was stable following addition of the disaccharide inhibitors. Thus, one may conclude that the site of inhibition is between lipid II formation and its polymerization into peptidoglycan via the transglycosylation process.
The synthetic disaccharide analogues target cell-wall synthesis in vivo, in intact Gram-positive bacteria, as assessed by both direct and indirect experimental results. They all inhibited incorporation of lysine into cell-wall material in intact Ent. faecalis with IC &! values within twofold of their respective MIC values on the same strain. In addition, the disaccharide analogues were bactericidal only to actively growing cells. Stationaryphase cells and cells pretreated with protein synthesis inhibitors or moenomycin were resistant to the bactericidal effects of the disaccharide analogues. Such differential killing is indicative of cell-wall synthesis inhibitors. Although little is known about the stringent response in Gram-positive bacteria, our data indicate that protein synthesis may be required for killing caused by the disaccharide analogues. Disaccharide analogues did not inhibit growth of C. albicans CCH442, or synthesis of 1,3-β-glucan from microsomes prepared from this strain (data not shown). The glucan-synthesis complex is known to be sensitive to agents which nonspecifically perturb membrane structure (Goldman et al., 1995 ; Ko et al., 1994) . Testing for overt cytotoxicity at concentrations well above the MIC in several mammalian cell lines suggests that these novel compounds (and moenomycin itself) are unlikely to induce nonspecific bacterial cell killing.
Our data are consistent with the following hypotheses and current base of knowledge regarding bacterial transglycosylases and their inhibition by moenomycin. Moenomycin is not a universal transglycosylase inhibitor, since it does not inhibit the monofunctional glycosyltransferase from Esc. coli (Di Berardino et al., 1996 ; Hara & Suzuki, 1984) , or the transglycosylase activity from Micrococcus luteus (Park & Matsuhashi, 1984) . Thus one would expect differential effects on bacteria depending on (a) the repertoire of transglycosylases inhibited, (b) the degree of inhibition and (c) the physiological consequences of inhibition. The pronounced bactericidal activity and subsequent rapid lysis of Esc. coli following treatment with moenomycin might result from inhibition of the transglycosylase activity of PBP1A and PBP1B, but it may also inhibit other transglycosylase enzymes such as PBP1C (Schiffer & Holtje, 1999) . Our data are consistent with the hypothesis that these synthetic disaccharide analogues of moenomycin target specific components of the transglycosylation process in Gram-positive bacteria in a unique manner not shared by the parent compound, moenomycin. Perhaps moenomycin inhibits an essential transglycosylase activity in Gram-positive bacteria, but one that accounts for only a minor fraction of the total peptidoglycan. Given the complexity of the interactions between the biosynthetic components involved in peptidoglycan synthesis (Holtje, 1996a (Holtje, , b, 1998 Koch, 1998 ; Vollmer et al., 1999 ; von Rechenberg et al., 1996) , further work will be required to understand the physiological consequences of inhibition of the transglycosylation process by different inhibitors. We are currently using these and other synthetic disaccharide analogues to clarify some of these processes.
